Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders
- 1 October 2000
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 9 (10) , 2331-2342
- https://doi.org/10.1517/13543784.9.10.2331
Abstract
Neuroimmunophilin ligands are a class of compounds that hold great promise for the treatment of nerve injuries and neurological disease. In contrast to neurotrophins (e.g., nerve growth factor), these compounds readily cross the blood-brain barrier, being orally effective in a variety of animal models of ischaemia, traumatic nerve injury and human neurodegenerative disorders. A further distinction is that neuroimmunophilin ligands act via unique receptors that are unrelated to the classical neurotrophic receptors (e.g., trk), making it unlikely that clinical trials will encounter the same difficulties found with the neurotrophins. Another advantage is that two neuroimmunophilin ligands (cyclosporin A and FK-506) have already been used in humans (as immunosuppressant drugs). Whereas both cyclosporin A and FK-506 demonstrate neuroprotective actions, only FK-506 and its derivatives have been clearly shown to exhibit significant neuroregenerative activity. Accordingly, the neuroprotective and neuroregenerativ...Keywords
This publication has 68 references indexed in Scilit:
- FK506 Accelerates Functional Recovery following Nerve Grafting in a Rat ModelPlastic and Reconstructive Surgery, 1999
- FK506 AND THE ROLE OF THE IMMUNOPHILIN FKBP-52 IN NERVE REGENERATION*Drug Metabolism Reviews, 1999
- Immunophilins in the Nervous SystemNeuron, 1998
- Oral administration of a nonimmunosuppressant FKBP-12 ligand speeds nerve regenerationNeuroReport, 1998
- A Nonimmunosuppressant FKBP-12 Ligand Increases Nerve RegenerationExperimental Neurology, 1997
- Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin ANature Medicine, 1997
- The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerveJournal of Neuroscience, 1995
- FK506 (TACROLIMUS) COMPARED WITH CYCLOSPORINE FOR PRIMARY IMMUNOSUPPRESSION AFTER PEDIATRIC LIVER TRANSPLANTATIONTransplantation, 1995
- Discovery of FK‐506 and UpdateAnnals of the New York Academy of Sciences, 1993
- FK 506 FOR LIVER, KIDNEY, AND PANCREAS TRANSPLANTATIONThe Lancet, 1989